Αρχική World News Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in... World News Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC Από Ogkologos - 21 Αυγούστου, 2025 648 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-426 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Active Surveillance for Low-Risk Prostate Cancer Continues to Rise 23 Ιουνίου, 2022 FDA Approves Nivolumab for Resected Oesophageal or Gastro-oesophageal Junction Cancer 25 Μαΐου, 2021 Woman Who Died For 27 Minutes Shares Haunting Message When Revived 12 Αυγούστου, 2019 Nivolumab Plus Chemotherapy Continues to Demonstrate Long-Term Survival Benefits in Patients... 24 Φεβρουαρίου, 2026 Φόρτωση περισσοτέρων HOT NEWS The Appraisal – Does a charity have a role in biotech... More Than One in 10 Patients With Lung Cancer Do Not... Cancer in My Community: Addressing Regional Cancer Disparities in Peru UK health inequalities: 20,000 more cancer cases a year in the...